HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Reg Stands To Classify TiO2 As ‘Suspected’ Carcinogen Beginning Summer 2021

Executive Summary

Reportedly, the Council of the European Union is considering member state objections and requests to extend the current scrutiny period beyond 4 December for a Commission delegated regulation that would classify titanium dioxide as a Category 2 carcinogen by inhalation. The move threatens to impact the marketing of sunscreens and other cosmetics in the EU that contain respirable TiO2 particles.

You may also be interested in...



EU Eyeing Carcinogen Tag For Titanium Dioxide Under CLP Reg; Why It Matters For Cosmetics

TiO2's nano-form use in spray sunscreens is already prohibited in the EU under the Cosmetics Regulation, but broader restrictions potentially extending to other cosmetic categories could be imposed down the line following a proposal from ECHA's Committee for Risk Assessment that the ingredient be CLP-classified as a suspected carcinogen when inhaled. There are also potential ramifications stateside to consider.

FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

US House Cosmetics Hearing: Preemption, FDA Ingredient Review Could Be Regulatory Reform Snags

Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.

Topics

UsernamePublicRestriction

Register

RS149402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel